Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 3INDUSTRY 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3CNS 2Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Thyroid Neoplasms 31Thyroid Cancer, Papillary 26Pheochromocytoma 23Adenocarcinoma, Follicular 23Adrenocortical Carcinoma 21Neuroendocrine Tumors 20Carcinoma, Medullary 17Somatostatinoma 14Insulinoma 14Thyroid Carcinoma, Anaplastic 13Pituitary Neoplasms 13Paraganglioma 13Carcinoma, Neuroendocrine 12Glucagonoma 11Carcinoma, Renal Cell 11Parathyroid Neoplasms 10Pancreatic Neoplasms 10Gastrinoma 10Carcinoma, Non-Small-Cell Lung 10Carcinoma, Hepatocellular 10Head and Neck Neoplasms 9Colonic Neoplasms 9Carcinoma, Islet Cell 9Breast Neoplasms 9Small Cell Lung Carcinoma 8Sarcoma 8Neoplasms 8Rectal Neoplasms 7Multiple Endocrine Neoplasia Type 1 7Adrenal Gland Neoplasms 7

Interventions

cixutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neuroectodermal Tumors × Endocrine × Clear all
NCT00831844 2015-03-30

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
116 enrolled 8 charts
CNSEndocrineGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Hepatoblastoma, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡